Participated · Seed · Apr 2026

Foundry Robotics aims to rebuild American manufacturing as an AI-first, assembly-focused, dual-use end-to-end manufacturer branded as the "Everything Factory." The company emphasizes software-defined, robotics-native production and plans to scale assembly operations using integrated robotics and AI. Its founding team includes veterans from Tesla, Blue Origin, Scale AI, and the Penn GRASP Lab. Foundry has publicly stated it closed over $19 million in total funding to date and is hiring across robotics, AI, and manufacturing to execute its plans. Early development began in a San Francisco loft during stealth, and the company highlights close collaboration with strategic VC and angel investors as it transitions to public operations.

Participated · Equity · Apr 2026

Via Separations develops modular filtration process solutions that electrify chemical separations, claiming reductions in energy needed for separations by up to 90 percent. Its technology has proven commercial performance in the pulp and paper sector, and the company plans to accelerate deployment into the refining and chemical industries. Via’s solutions aim to lower energy use, improve uptime and strengthen operational resilience while reducing emissions. The company is led by CEO Shreya Dave and recently raised $36M in new funding from a group including Climate Investment, Aramco Ventures and Marathon Petroleum Corporation, alongside existing investors.

Led · Seed · Dec 2025

Founded in 2023 and headquartered in Riyadh, Newera.ai builds generative and agentic AI tools that help Saudi enterprises boost productivity, enhance collaboration, and accelerate innovation. Its platform enables organizations to create, integrate, and deploy AI systems that plug directly into real business processes. The company focuses on delivering Saudi-specific large-language-model capabilities and domain-adapted agents rather than generic off-the-shelf models. Proceeds from its recent financing will bolster research and development, deepen product functionality, and support go-to-market efforts within the Kingdom. Management positions the company as a trusted AI partner for enterprises navigating digital transformation mandates. Although still pre-revenue disclosures have not been made public, the team emphasizes quick commercialization of bespoke AI workflows for large local customers. Continued investment in localized data sets and compliance with Saudi regulatory requirements underpin its product roadmap.

Led · Seed · Nov 2025

QSimulate is a Boston-based technology company focused on applying quantum simulation to problems in drug discovery and broader industrial R&D. Its core offering is a cloud-based platform that models molecular interactions with quantum-level precision, helping researchers optimize leads, especially covalent drug molecules and compounds interacting with metal ions. In November 2025 the firm released QUELO v2.3, adding enhanced sampling techniques and support for larger molecules and peptide drugs. Current collaborations span multinational enterprises such as Google, Mitsui, and JT Pharma, underscoring early commercial traction. The company plans to use newly raised capital to scale operations and broaden its platform’s capabilities to meet growing partner demand. Led by CEO Toru Shiozaki, QSimulate has secured $11 million in total funding to date.

Participated · Seed · Feb 2024

Elemind develops a wearable neurotechnology platform that uses proprietary signal-processing algorithms and AI to read individual brainwaves and deliver tailored, real-time stimulation—an approach the company calls “electric medicine.” The company’s first product is positioned as a general wellness device and is expected to be revealed in the coming months. Elemind emerged from stealth after conducting research since 2019 and holds three critical patents covering its core algorithms and dynamic neurostimulation techniques. Its technology is supported by five clinical trials and multiple peer-reviewed publications (including Nature Communications) showing faster sleep induction (up to 74% faster), rapid suppression of essential tremor, memory boosts, increased pain thresholds, and enhanced sedation (the latter in peer review). The founding team includes neuroscientists and researchers affiliated with MIT, Imperial College London, Harvard Medical School, and UC Berkeley. The company plans to use the recently closed seed funding to further develop and validate its wearable product and build applications across neurological conditions.